Promising data in depression associated with emotional blunting or trauma

Treatment for depression should be tailored to individuals’ history and presentation. Patients with reduced emotional responsiveness and those abused early in life – important and vulnerable groups in whom response to antidepressants had previously been little studied – were the focus of a satellite symposium at EPA 2021 Virtual.

While anhedonia is the reduced ability to experience and anticipate pleasure, emotional blunting can be described as reduced emotional responsiveness – either positive and negative.1,2 Both impose burdens on patients with major depressive disorder (MDD), and both are common.

  • Franken et al found around 75% of patients with MDD reported anhedonia1
  • Guy Goodwin and colleagues in Oxford found emotional blunting in 46% of treated MDD patients2
  • In a survey of patients in New  Zealand, around 60% of those taking a range of different antidepressants – both SSRIs and an SNRI -- reported feeling emotionally numb3
  • The effect of emotional blunting on decision making  can reduce adherence and so compromise efficacy.4 In a recent study, 35% of patients discontinued treatment because of it.5

Central dopaminergic, mesolimbic and mesocortical reward pathways are implicated in anhedonia,2 and emotional numbing may relate to reduced dopamine or glutamatergic activity6

In the COMPLETE study, use of a multimodal antidepressant was associated with reduced emotional blunting and improved functioning

 

Promising new data in emotional blunting

So there is great interest in the results of the recent COMPLETE study involving an antidepressant that combines modulation of activity at a range of serotonin receptor subtypes with inhibition of the serotonin transporter and a positive effect on downstream dopamine.7,8

The study involved patients with only a partial response to an SSRI or SNRI who experienced emotional blunting on treatment and who wanted to switch agent.

Presenting the data at EPA 2021 Virtual, Andrea Fagiolini (University of Siena, Italy) reported that the multimodal antidepressant significantly improved emotional blunting as measured by the Oxford Depression Questionnaire.9 After eight weeks of treatment, 50% of patients reported no blunting.

Improvement in emotional blunting was accompanied by improvement in overall functioning (and in work, family and social domains) and greater motivation and energy (mental, social and physical).9 Ongoing studies are assessing the role of this agent in patients with anhedonia.

 

Prospects also enhanced in trauma-related MDD

The multimodal agent improved symptoms and functioning in MDD patients reporting childhood or recent trauma16

Childhood trauma can increase the risk of early-onset major depression, and is associated with a relapsing and chronic course.10

The many adults who have a history of childhood trauma are significantly less likely than others to benefit from commonly used treatments.11

According to the international Study to Predict Optimized Treatment for Depression (iSPOT-D), patients with MDD who had been abused when aged 4-7 years were 1.6 times less likely than non-abused people to achieve response or remission when taking an SSRI or SNRI.11

Lower risk of relapse over 24 weeks

Professor Fagiolini described a series of studies in patients with MDD who had reported either childhood or recent trauma using an antidepressant with multimodal effects on neural pathways including enhanced glutamate signaling.12-15

Meta-analysis of the short-term studies showed the multimodal agent significantly improved short and long-term symptoms, including anxiety and well as depression, both in patients with childhood trauma and in those with recent trauma.16

In a long-term study, use of the multimodal agent was associated with improved symptoms and better overall functioning and health-related quality of life when baseline values were compared with those at week 48, and with a significantly lower risk of depression relapse within 24 weeks.16

 

Educational financial support for the symposium was provided by H. Lundbeck A/S, who also funded the studies reported in patients with depression associated with emotional blunting and childhood trauma.

 

For the latest updates on sea.progress.im, subscribe to our Telegram Channel https://bit.ly/telePiM

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

References

1. Franken IHA et al. J Affect Disord 2007;99:83-9;

2. Goodwin GM et al. J Affect Disord 2017;221:31-5

 

3. Read J et al. Psychiatry Res 2014;216:67-73

 

4. Sirey JA et al. JAMA Psychiatry 2017;74:1129-35

 

6. Sansone RA, Sansone LA. Psychiatry (Edgmont) 2010;7:14-83

 

7. Sanchez C et al. Pharmacol Ther 2015;145:43-57;

8. Areberg J et al. Basic Clin Pharmacol Toxicol 2012;110:401-4

 

9. Fagiolini A et al. J Affect Disord 2021;283:472-9

 

10. Hovens J. Emotional Scars. Impact of Childhood Trauma on Depressive and Anxiety Disorders 2015; Ch 7: pp115-36

 

11. Williams LM et al. Transl Psychiatry 2016;6:e799

 

12.  Guilloux JP et al. Neuropharmacology 2013;73:147-59

 

13. Pehrson AL et al. Eur Neuropsychopharmacol 2013;23:133-45

 

14. Mørk A et al. Pharmacol Biochem Behav 2013;105:41-50

 

15. Pehrson AL, Sanchez C. CNS Spectr 2014;19:121-33

 

16. Cronquist Christensen M et al. J Affect Disord 2020;263:258-66

 

You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country